Author's response to reviews

Title: Myelin associated glycoprotein (MAG) related neuropathy associated with Psoriasis: a case report

Authors:

Ken-ya Murata (kemurata@wakayama-med.ac.jp)  
Hideto Miwa (h.miwa@juntendo-nerima.jp)  
Tomoyoshi Kondo (t-kondo@yushikai.jp)

Version: 2 Date: 7 November 2012

Author's response to reviews:

October 6 2012

Professor Michael Kidd AM  
Editor in chief, Journal of Medical Case Reports

Re: Manuscript 1518431531753981 (Myelin associated glycoprotein (MAG) related neuropathy associated with Psoriasis: a case report by Murata et al.)

Dear Professor Michael Kidd AM#

Thank you for the opportunity to resubmit our paper to Journal of Medical Case Reports. The comments of the reviewers have been helpful in the revision of our manuscript. We have addressed the questions raised by the referees as follows:

Reviewer #1

1) As suggested by the reviewer, I quoted a new article (Eur Neurol. 2001; 46(3): 167-8) and discussed the treatment combination of IVIG and interferon in our case. We described this in the revised Discussion section, page 5 line 19-22. I added the new reference in the revised Reference section, page 8 line 7-9. The citation number is 3.

Reviewer #2

1) As the reviewer pointed out, it is necessary to describe whether MAG related neuropathy and Psoriasis are linked or not. I consider that this co-occurrence is by chance. Recently, anti-TNF-alpha therapy was introduced in patients with Psoriasis or Psoriasis arthritis. On the other hand, this therapy may be harmful to cases of demyelinating neuropathy including MAG related neuropathy. Therefore, it is very important to recognize the coexistence of MAG neuropathy and Psoriasis to avoid side effect of ant-TNF-alpha therapy. From these points, this paper is worth reporting. We have now mentioned this in Discussion section, page 6 line 1-6, line 8-10 and line 13-19.
2) As the reviewer pointed out, IVIg therapy is not a standard therapy in patients with MAG related neuropathy. We mentioned this in the Discussion section, page 5 line 17-19.

3) As the reviewer pointed out, it is not clear how long IVIG therapy was effective. We have mentioned this in the revised Case presentation section, page 5 line 10.

In addition to the reviewers’ comments, we added patients’ ethnicity in the case presentation section. We have mentioned this in the revised abstract section, page 2 line 9, and in the revised Case presentation section, page 3 line 13.

We have also asked an English Editorial Company to recheck our manuscript to avoid grammatical errors and poor English expression. The attached paper entitled "Myelin associated glycoprotein (MAG) related neuropathy associated with Psoriasis" has been carefully reviewed by an experienced medical editor whose first language is English and who specializes in the editing of papers written by physicians and scientists whose native language is not English.

We believe that we have responded in full to the comments of the reviewers and trust you will now find the paper suitable for publication in the Journal of Medical Case Reports.

I have attached the revised manuscript with highlights and Figures.

I would very much like to thank you for your consideration. If you require any further questions, please do not hesitate to contact me.

Yours sincerely,

Kenya Murata, MD, PhD
Associate Professor
Department of Neurology
Wakayama Medical University
E-mail: kemurata@wakayama-med.ac.jp